Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Complementary adenoviral vectors for oncolysis.

R Alemany1, S Lai, Y C Lou

  • 1Gene Therapy Program, University of Alabama, Birmingham 35294, USA.

Cancer Gene Therapy
|March 17, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and safety of atezolizumab plus bevacizumab in MSI-like metastatic colorectal cancer: a multicenter, single-arm, phase II, open-label clinical trial.

ESMO open·2025
Same author

Oncolytic adenovirus coding for shedding-resistant MICA enhances immune responses against tumors.

Cancer immunology, immunotherapy : CII·2024
Same author

Human Menstrual Blood-Derived Mesenchymal Stem Cells as Potential Cell Carriers for Oncolytic Adenovirus.

Stem cells international·2017
Same author

Probing lepton flavour violation via neutrinoless [Formula: see text] decays with the ATLAS detector.

The European physical journal. C, Particles and fields·2017
Same author

A new method to distinguish hadronically decaying boosted <i>Z</i> bosons from <i>W</i> bosons using the ATLAS detector.

The European physical journal. C, Particles and fields·2017
Same author

Search for supersymmetry at [Formula: see text] TeV in final states with jets and two same-sign leptons or three leptons with the ATLAS detector.

The European physical journal. C, Particles and fields·2017

Engineered adenoviruses (Ads) were split into two complementary viruses for oncolytic virotherapy. This system selectively targets tumor cells, showing promise for cancer treatment.

Area of Science:

  • Oncolytic virotherapy
  • Viral oncology
  • Gene therapy

Background:

  • Replication-competent adenoviruses (Ads) have been explored for oncolytic virotherapy.
  • Genetically engineered Ads demonstrate selective tumor cell lysis.
  • Previous strategies utilized single viral vectors.

Purpose of the Study:

  • To develop a novel oncolytic virotherapy system using two complementary adenoviruses.
  • To engineer vectors with tumor-specific replication and gene expression.
  • To evaluate the safety and efficacy of this dual-vector system in preclinical models.

Main Methods:

  • Human Ad type 5 genome split into two defective complementary vectors: GT5610 and AdHbeta.
  • GT5610 engineered with E1A under alpha-fetoprotein promoter for tumor-specific control.

Related Experiment Videos

  • Vectors designed for heterologous reporter gene expression and large foreign DNA capacity.
  • In vitro studies using hepatocarcinoma cells and in vivo studies with human hepatocarcinomas xenografted in SCID mice.

    • Main Results:

    • Coinfection of hepatocarcinoma cells resulted in selective cell lysis and copropagation.
    • Demonstrated oncolytic spread of complementary vectors in vivo via intratumoral injection.
    • Vectors showed tumor-specific replication and gene expression.
    • The dual-vector system exhibited safety and significant gene capacity.

    Conclusions:

    • This complementary adenoviral vector system offers enhanced safety and gene capacity for oncolytic virotherapy.
    • The tumor-specific replication and spread present a potential therapeutic advantage over single-virus systems.
    • Further development could lead to improved cancer treatment strategies.